Survivin in autoimmune diseases

Autoimmunity Reviews

Volumn 16, Issue 8, 2017, Pages 845-855

  Gravina, G ^a   Wasen C ^a   Garcia Bonete, M J ^b   Turkkila, M ^a   Erlandsson, M C ^a,c   Toyra Silfversward S ^a   Brisslert, M ^a   Pullerits, R ^a,c   Andersson, K M ^a   Katona, G ^b   Bokarewa, M I ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Hypoxia; Inflammation; Smoking; Survivin; Therapy

Indexed keywords

BARICITINIB; EZN 3042; GATAPARSEN; MACITENTAN; PRASTERONE; PROTEIN INHIBITOR; SEPANTRONIUM BROMIDE; SHORT HAIRPIN RNA; STAT3 PROTEIN; SURVIVIN; TAURINE CHLORIDE; TAURINE DERIVATIVE; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; DRUG TARGETING; HEMATOPOIESIS; HUMAN; HYPOXIA; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LICHEN PLANUS; NEUROPATHOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; SUN EXPOSURE; SYSTEMIC SCLEROSIS; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION; SUNLIGHT;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; HEMATOPOIESIS; HUMANS; HYPOXIA; IMMUNITY, INNATE; INFLAMMATION; INHIBITOR OF APOPTOSIS PROTEINS; PROTEIN CONFORMATION; SMOKING; SUNLIGHT;

EID: 85020094366     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.05.016     Document Type: Review

References (181)

1. Ambrosini, G., Adida, C., Altieri, D.C., A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997), 917–921.
2. Caldas, H., Honsey, L.E., Altura, R.A., Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer, 4, 2005, 11.
3. Mahotka, C., Wenzel, M., Springer, E., Gabbert, H.E., Gerharz, C.D., Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999), 6097–6102.
4. Ling, X., Cheng, Q., Black, J.D., Li, F., Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem 282 (2007), 27204–27214.
5. Shi, K., An, J., Shan, L., Jiang, Q., Li, F., Ci, Y., et al. Survivin-2B promotes autophagy by accumulating IKK alpha in the nucleus of selenite-treated NB4 cells. Cell Death Dis, 5, 2014, e1071.
6. Duffy, M.J., O'Donovan, N., Brennan, D.J., Gallagher, W.M., Ryan, B.M., Survivin: a promising tumor biomarker. Cancer Lett 249 (2007), 49–60.
7. Mahotka, C., Liebmann, J., Wenzel, M., Suschek, C.V., Schmitt, M., Gabbert, H.E., et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9 (2002), 1334–1342.
8. Carmena, M., Wheelock, M., Funabiki, H., Earnshaw, W.C., The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol 13 (2012), 789–803.
9. Niedzialkowska, E., Wang, F., Porebski, P.J., Minor, W., Higgins, J.M., Stukenberg, P.T., Molecular basis for phosphospecific recognition of histone H3 tails by Survivin paralogues at inner centromeres. Mol Biol Cell 23 (2012), 1457–1466.
10. Altieri, D.C., Survivin and IAP proteins in cell-death mechanisms. Biochem J 430 (2010), 199–205.
11. Arora, V., Cheung, H.H., Plenchette, S., Micali, O.C., Liston, P., Korneluk, R.G., Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 282 (2007), 26202–26209.
12. Zumbragel, F.K., Machtens, D.A., Curth, U., Luder, C.G., Reubold, T.F., Eschenburg, S., Survivin does not influence the anti-apoptotic action of XIAP on caspase-9. Biochem Biophys Res Commun 482 (2017), 530–535.
13. Du, C., Fang, M., Li, Y., Li, L., Wang, X., Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000), 33–42.
14. Andersson, K.M., Turkkila, M., Erlandsson, M.C., Bossios, A., Silfversward, S.T., Hu, D., et al. Survivin controls biogenesis of microRNA in smokers: a link to pathogenesis of rheumatoid arthritis. Biochim Biophys Acta 2017 (1863), 663–673.
15. Fukuda, S., Pelus, L.M., Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34 + hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 1 (2002), 322–326.
16. Fukuda, S., Mantel, C.R., Pelus, L.M., Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 103 (2004), 120–127.
17. Fukuda, S., Pelus, L.M., Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98 (2001), 2091–2100.
18. Okada, H., Bakal, C., Shahinian, A., Elia, A., Wakeham, A., Suh, W.K., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 199 (2004), 399–410.
19. Xing, Z., Conway, E.M., Kang, C., Winoto, A., Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199 (2004), 69–80.
20. Altznauer, F., Martinelli, S., Yousefi, S., Thurig, C., Schmid, I., Conway, E.M., et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 199 (2004), 1343–1354.
21. Koslen, R.H., Two-stage maxillary ridge augmentation using durapatite. J Oral Implantol 13 (1987), 428–441.
22. Mesri, M., Morales-Ruiz, M., Ackermann, E.J., Bennett, C.F., Pober, J.S., Sessa, W.C., et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 158 (2001), 1757–1765.
23. Gurbuxani, S., Xu, Y., Keerthivasan, G., Wickrema, A., Crispino, J.D., Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A 102 (2005), 11480–11485.
24. Fukuda, S., Abe, M., Onishi, C., Taketani, T., Purevsuren, J., Yamaguchi, S., et al. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol, 2011, 2011, 946936.
25. Leung, C.G., Xu, Y., Mularski, B., Liu, H., Gurbuxani, S., Crispino, J.D., Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 204 (2007), 1603–1611.
26. Fukuda, S., Hoggatt, J., Singh, P., Abe, M., Speth, J.M., Hu, P., et al. Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1. Leukemia 29 (2015), 433–440.
27. Fukuda, S., Foster, R.G., Porter, S.B., Pelus, L.M., The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100 (2002), 2463–2471.
28. Mull, A.N., Klar, A., Navara, C.S., Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency. Stem Cell Res 12 (2014), 539–549.
29. Kapinas, K., Kim, H., Mandeville, M., Martin-Buley, L.A., Croce, C.M., Lian, J.B., et al. microRNA-mediated survivin control of pluripotency. J Cell Physiol 230 (2015), 63–70.
30. Song, J., Lei, F.T., Xiong, X., Haque, R., Intracellular signals of T cell costimulation. Cell Mol Immunol 5 (2008), 239–247.
31. Lei, F., Song, J., Haque, R., Xiong, X., Fang, D., Wu, Y., et al. Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation. Eur J Immunol 43 (2013), 1914–1924.
32. Kornacker, M., Verneris, M.R., Kornacker, B., Scheffold, C., Negrin, R.S., Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 76 (2001), 169–173.
33. Andersson, K.M., Brisslert, M., Cavallini, N.F., Svensson, M.N., Welin, A., Erlandsson, M.C., et al. Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6. Oncotarget 6 (2015), 20043–20057.
34. Niedbala, W., Cai, B., Liu, H., Pitman, N., Chang, L., Liew, F.Y., Nitric oxide induces CD4 + CD25 + Foxp3 regulatory T cells from CD4 + CD25 T cells via p53, IL-2, and OX40. Proc Natl Acad Sci U S A 104 (2007), 15478–15483.
35. Miletic, A.V., Jellusova, J., Cato, M.H., Lee, C.R., Baracho, G.V., Conway, E.M., et al. Essential role for survivin in the proliferative expansion of progenitor and mature B cells. J Immunol 196 (2016), 2195–2204.
36. Kusner, L.L., Ciesielski, M.J., Marx, A., Kaminski, H.J., Fenstermaker, R.A., Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One, 9, 2014, e102231.
37. Bokarewa, M., Lindblad, S., Bokarew, D., Tarkowski, A., Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 7 (2005), R349–R358.
38. Svensson, B., Hafstrom, I., Forslind, K., Albertsson, K., Tarkowski, A., Bokarewa, M., Increased expression of proto-oncogene survivin predicts joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med 42 (2010), 45–54.
39. Turkkila, M., Andersson, K.M., Amu, S., Brisslert, M., Erlandsson, M.C., Silfversward, S., et al. Suppressed diversity of survivin splicing in active rheumatoid arthritis. Arthritis Res Ther, 17, 2015, 175.
40. Liu, J., Cao, X., Cellular and molecular regulation of innate inflammatory responses. Cell Mol Immunol 13 (2016), 711–721.
41. Skokowa, J., Cario, G., Uenalan, M., Schambach, A., Germeshausen, M., Battmer, K., et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 12 (2006), 1191–1197.
42. Hu, H., Shikama, Y., Matsuoka, I., Kimura, J., Terminally differentiated neutrophils predominantly express Survivin-2 alpha, a dominant-negative isoform of survivin. J Leukoc Biol 83 (2008), 393–400.
43. Navegantes, K.C., de Souza, Gomes R., Pereira, P.A., Czaikoski, P.G., Azevedo, C.H., Monteiro, M.C., Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity. J Transl Med, 15, 2017, 36.
44. Singh, P., Hoggatt, J., Hu, P., Speth, J.M., Fukuda, S., Breyer, R.M., et al. Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells. Blood 119 (2012), 1671–1682.
45. Andersson, S.E., Svensson, M.N., Erlandsson, M.C., Dehlin, M., Andersson, K.M., Bokarewa, M.I., Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One, 7, 2012, e47668.
46. van Holten, J., Smeets, T.J., Blankert, P., Tak, P.P., Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 64 (2005), 1780–1782.
47. Bave, U., Nordmark, G., Lovgren, T., Ronnelid, J., Cajander, S., Eloranta, M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 (2005), 1185–1195.
48. O'Keeffe, M., Mok, W.H., Radford, K.J., Human dendritic cell subsets and function in health and disease. Cell Mol Life Sci 72 (2015), 4309–4325.
49. Li, Y., Ding, J., Optimized generation of survivin-specific cytotoxic T lymphocytes against lung cancer. Mol Med Rep 12 (2015), 2169–2174.
50. Mokuda, S., Miyazaki, T., Ubara, Y., Kanno, M., Sugiyama, E., Takasugi, K., et al. CD1a + survivin + dendritic cell infiltration in dermal lesions of systemic sclerosis. Arthritis Res Ther, 17, 2015, 275.
51. Sisson, T.H., Maher, T.M., Ajayi, I.O., King, J.E., Higgins, P.D., Booth, A.J., et al. Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol 3 (2012), 657–664.
52. Terasaki, Y., Terasaki, M., Urushiyama, H., Nagasaka, S., Takahashi, M., Kunugi, S., et al. Role of survivin in acute lung injury: epithelial cells of mice and humans. Lab Invest 93 (2013), 1147–1163.
53. Park, M.C., Chung, S.J., Park, Y.B., Lee, S.K., Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis. Clin Exp Rheumatol 26 (2008), 881–886.
54. Baran, M., Mollers, L.N., Andersson, S., Jonsson, I.M., Ekwall, A.K., Bjersing, J., et al. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 13 (2009), 3797–3808.
55. Dharmapatni, A.A., Smith, M.D., Findlay, D.M., Holding, C.A., Evdokiou, A., Ahern, M.J., et al. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther, 11, 2009, R13.
56. Sharief, M.K., Noori, M.A., Douglas, M.R., Semra, Y.K., Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol 9 (2002), 503–510.
57. Salem, A.M., Ahmed, H.H., Atta, H.M., Ghazy, M.A., Aglan, H.A., Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats. Cell Biol Int 38 (2014), 1367–1383.
58. Siddiquee, K., Zhang, S., Guida, W.C., Blaskovich, M.A., Greedy, B., Lawrence, H.R., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104 (2007), 7391–7396.
59. Kawakami, H., Tomita, M., Matsuda, T., Ohta, T., Tanaka, Y., Fujii, M., et al. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115 (2005), 967–974.
60. Lee, C.W., Raskett, C.M., Prudovsky, I., Altieri, D.C., Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 68 (2008), 5273–5281.
61. Kim, P.J., Plescia, J., Clevers, H., Fearon, E.R., Altieri, D.C., Survivin and molecular pathogenesis of colorectal cancer. Lancet 362 (2003), 205–209.
62. Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21 (2002), 2613–2622.
63. Hoffman, W.H., Biade, S., Zilfou, J.T., Chen, J., Murphy, M., Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277 (2002), 3247–3257.
64. Zhang, T., Otevrel, T., Gao, Z., Gao, Z., Ehrlich, S.M., Fields, J.Z., et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61 (2001), 8664–8667.
65. Guha, M., Plescia, J., Leav, I., Li, J., Languino, L.R., Altieri, D.C., Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 69 (2009), 4954–4958.
66. Chen, Y., Li, D., Liu, H., Xu, H., Zheng, H., Qian, F., et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther 11 (2011), 14–21.
67. Li, X., Liu, X., Xu, Y., Liu, J., Xie, M., Ni, W., et al. KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1alpha. Int J Oncol 45 (2014), 1507–1514.
68. Li, X., He, Y., Xu, Y., Huang, X., Liu, J., Xie, M., et al. KLF5 mediates vascular remodeling via HIF-1alpha in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 310 (2016), L299–L310.
69. Wang, Y.F., Ma, S.R., Wang, W.M., Huang, C.F., Zhao, Z.L., Liu, B., et al. Inhibition of survivin reduces HIF-1alpha, TGF-beta1 and TFE3 in salivary adenoid cystic carcinoma. PLoS One, 9, 2014, e114051.
70. Zhang, B., Yin, C.P., Zhao, Q., Yue, S.W., Upregulation of HIF-1alpha by hypoxia protect neuroblastoma cells from apoptosis by promoting survivin expression. Asian Pac J Cancer Prev 15 (2014), 8251–8257.
71. Horowitz, J.C., Ajayi, I.O., Kulasekaran, P., Rogers, D.S., White, J.B., Townsend, S.K., et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol 44 (2012), 158–169.
72. Dabral, S., Tian, X., Kojonazarov, B., Savai, R., Ghofrani, H.A., Weissmann, N., et al. Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. Eur Respir J 48 (2016), 1137–1149.
73. Sayeed, A., Konduri, S.D., Liu, W., Bansal, S., Li, F., Das, G.M., Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 67 (2007), 7746–7755.
74. Perricone, C., Versini, M., Ben-Ami, D., Gertel, S., Watad, A., Segel, M.J., et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 15 (2016), 354–374.
75. Oloris, S.C., Frazer-Abel, A.A., Jubala, C.M., Fosmire, S.P., Helm, K.M., Robinson, S.R., et al. Nicotine-mediated signals modulate cell death and survival of T lymphocytes. Toxicol Appl Pharmacol 242 (2010), 299–309.
76. Jin, Q., Menter, D.G., Mao, L., Hong, W.K., Lee, H.Y., Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 29 (2008), 1614–1622.
77. Zeng, F., Li, Y.C., Chen, G., Zhang, Y.K., Wang, Y.K., Zhou, S.Q., et al. Nicotine inhibits cisplatin-induced apoptosis in NCI-H446 cells. Med Oncol 29 (2012), 364–373.
78. Cucina, A., Dinicola, S., Coluccia, P., Proietti, S., D'Anselmi, F., Pasqualato, A., et al. Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J Surg Res 178 (2012), 233–241.
79. Dasgupta, P., Kinkade, R., Joshi, B., Decook, C., Haura, E., Chellappan, S., Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 103 (2006), 6332–6337.
80. Hirano, H., Maeda, H., Takeuchi, Y., Susaki, Y., Kobayashi, R., Hayashi, A., et al. Association of cigarette smoking with the expression of nuclear survivin in pathological stage IA lung adenocarcinomas. Med Mol Morphol 47 (2014), 196–200.
81. Svensson, B., Hafstrom, I., Erlandsson, M.C., Forslind, K., Bokarewa, M.I., Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther, 16, 2014, R12.
82. Wasen, C., Turkkila, M., Bossios, A., Erlandsson, M., Andersson, K.M., Ekerljung, L., et al. Smoking activates cytotoxic CD8 + T cells and causes survivin release in rheumatoid arthritis. J Autoimmun, 2017.
83. Hempel, S., Graham, G.D., Fu, N., Estrada, E., Chen, A.Y., Miake-Lye, I., et al. A systematic review of modifiable risk factors in the progression of multiple sclerosis. Mult Scler 23 (2017), 525–533.
84. Maniaol, A.H., Boldingh, M., Brunborg, C., Harbo, H.F., Tallaksen, C.M., Smoking and socio-economic status may affect myasthenia gravis. Eur J Neurol 20 (2013), 453–460.
85. Aziz, M.H., Ghotra, A.S., Shukla, Y., Ahmad, N., Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin. Photochem Photobiol 80 (2004), 602–608.
86. Cooper, S.J., Bowden, G.T., Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets 7 (2007), 325–334.
87. Dallaglio, K., Palazzo, E., Marconi, A., Dumas, M., Truzzi, F., Lotti, R., et al. Endogenous survivin modulates survival and proliferation in UVB-treated human keratinocytes. Exp Dermatol 18 (2009), 464–471.
88. Gambichler, T., Tigges, C., Dith, A., Skrygan, M., Scola, N., Altmeyer, P., et al. Impact of etanercept treatment on ultraviolet B-induced inflammation, cell cycle regulation and DNA damage. Br J Dermatol 164 (2011), 110–115.
89. Sharief, M.K., Semra, Y.K., Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119 (2001), 358–364.
90. McMurtry, M.S., Archer, S.L., Altieri, D.C., Bonnet, S., Haromy, A., Harry, G., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115 (2005), 1479–1491.
91. Markham, T., Mathews, C., Rogers, S., Mullan, R., Bresnihan, B., Fitzgerald, O., et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br J Dermatol 155 (2006), 1191–1196.
92. de Souza, H.S., West, G.A., Rebert, N., de la Motte, C., Drazba, J., Fiocchi, C., Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology 143 (2012), 1017–1026, e9.
93. Chaiyarit, P., Jintakanon, D., Klanrit, P., Siritapetawee, M., Thongprasom, K., Immunohistochemical analyses of survivin and heat shock protein 90 expression in patients with oral lichen planus. J Oral Pathol Med 38 (2009), 55–62.
94. Smith, M.D., Weedon, H., Papangelis, V., Walker, J., Roberts-Thomson, P.J., Ahern, M.J., Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49 (2010), 862–875.
95. Ahn, J.K., Oh, J.M., Lee, J., Bae, E.K., Ahn, K.S., Cha, H.S., et al. Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation 33 (2010), 381–388.
96. Jenko, B., Praprotnik, S., Cucnik, S., Rotar, Z., Tomsic, M., Dolzan, V., Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients. Pharmacogenomics 17 (2016), 45–49.
97. Isgren, A., Forslind, K., Erlandsson, M., Axelsson, C., Andersson, S., Lund, A., et al. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum 41 (2012), 652–657.
98. Levitsky, A., Erlandsson, M.C., van Vollenhoven, R.F., Bokarewa, M.I., Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial. BMC Med, 13, 2015, 247.
99. Chun-Lai, T., Murad, S., Erlandsson, M.C., Hussein, H., Sulaiman, W., Dhaliwal, J.S., et al. Recognizing rheumatoid arthritis: oncoprotein survivin opens new possibilities: a population-based case-control study. Medicine (Baltimore), 94, 2015, e468.
100. Bokarewa, M., Brink, M., Erlandsson, M., Rantapaa, Dahlqvist S., Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study. Arthritis Res Ther, 16, 2014, R45.
101. Galeotti, L., Adrian, K., Berg, S., Tarkowski, A., Bokarewa, M., Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin Exp Rheumatol 26 (2008), 373–378.
102. Andersson, K.M., Svensson, M.N., Erlandsson, M.C., Jonsson, I.M., Bokarewa, M.I., Down-regulation of survivin alleviates experimental arthritis. J Leukoc Biol 97 (2015), 135–145.
103. Jiang, Y., de Bruin, A., Caldas, H., Fangusaro, J., Hayes, J., Conway, E.M., et al. Essential role for survivin in early brain development. J Neurosci 25 (2005), 6962–6970.
104. Baratchi, S., Kanwar, R.K., Kanwar, J.R., Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. J Neuroimmunol 233 (2011), 18–28.
105. Sehara, Y., Sawicka, K., Hwang, J.Y., Latuszek-Barrantes, A., Etgen, A.M., Zukin, R.S., Survivin is a transcriptional target of STAT3 critical to estradiol neuroprotection in global ischemia. J Neurosci 33 (2013), 12364–12374.
106. Chu, S.F., Zhang, Z., Zhang, W., Zhang, M.J., Gao, Y., Han, N., et al. Upregulating the expression of Survivin-HBXIP complex contributes to the protective role of IMM-H004 in transient global cerebral ischemia/reperfusion. Mol Neurobiol 54 (2017), 524–540.
107. Lei, X., Chao, H., Zhang, Z., Lv, J., Li, S., Wei, H., et al. Neuroprotective effects of quercetin in a mouse model of brain ischemic/reperfusion injury via anti-apoptotic mechanisms based on the Akt pathway. Mol Med Rep 12 (2015), 3688–3696.
108. Johnson, E.A., Svetlov, S.I., Wang, K.K., Hayes, R.L., Pineda, J.A., Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats. Exp Brain Res 167 (2005), 17–26.
109. Li, Q., Tsuneki, M., Krauthammer, M., Couture, R., Schwartz, M., Madri, J.A., Modulation of Sox10, HIF-1alpha, Survivin, and YAP by minocycline in the treatment of neurodevelopmental handicaps following hypoxic insult. Am J Pathol 185 (2015), 2364–2378.
110. Sriramoju, B., Kanwar, R.K., Kanwar, J.R., Nanoformulated mutant SurR9-C84A: a possible key for Alzheimer's and its associated inflammation. Pharm Res 32 (2015), 2787–2797.
111. Koudriavtseva, T., Mainero, C., Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response. Neural Regen Res 11 (2016), 1727–1730.
112. Pender, M.P., Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351 (1998), 978–981.
113. Sharief, M.K., Semra, Y.K., Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. Arch Neurol 59 (2002), 1115–1121.
114. Gilhus, N.E., Myasthenia gravis. N Engl J Med 375 (2016), 2570–2581.
115. Brunasso, A.M., Massone, C., Update on the pathogenesis of scleroderma: focus on circulating progenitor cells. F1000Res, 2016, 5.
116. Koike, Y., Muroi, E., Yoshizaki, A., Ogawa, F., Yanaba, K., Takenaka, M., et al. Autoantibody against survivin in patients with systemic sclerosis. J Rheumatol 37 (2010), 1864–1870.
117. Hsu, V.M., Chung, L., Hummers, L.K., Wigley, F., Simms, R., Bolster, M., et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 44 (2014), 55–62.
118. Guignabert, C., Tu, L., Le Hiress, M., Ricard, N., Sattler, C., Seferian, A., et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 22 (2013), 543–551.
119. Zhao, L., Chen, C.N., Hajji, N., Oliver, E., Cotroneo, E., Wharton, J., et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126 (2012), 455–467.
120. Zhang, S., Liu, B., Fan, Z., Wang, D., Liu, Y., Li, J., et al. Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K(+) channels. Mol Med Rep 13 (2016), 3415–3422.
121. Fan, Z., Liu, B., Zhang, S., Liu, H., Li, Y., Wang, D., et al. YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels. Clin Exp Hypertens 37 (2015), 381–387.
122. Yan, J., Shen, Y., Wang, Y., Li, B.B., Increased expression of hypoxia-inducible factor-1alpha in proliferating neointimal lesions in a rat model of pulmonary arterial hypertension. Am J Med Sci 345 (2013), 121–128.
123. Huang, Z., Liu, Z., Luo, Q., Zhao, Z., Zhao, Q., Zheng, Y., et al. Glycoprotein 130 inhibitor ameliorates monocrotaline-induced pulmonary hypertension in rats. Can J Cardiol 32 (2016), 1356.e1–1356.e10.
124. Cao, S.S., Epithelial, E.R., Stress in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 22 (2016), 984–993.
125. Fogt, F., Poremba, C., Shibao, K., Itoh, H., Kohno, K., Zimmerman, R.L., et al. Expression of survivin, YB-1, and KI-67 in sporadic adenomas and dysplasia-associated lesions or masses in ulcerative colitis. Appl Immunohistochem Mol Morphol 9 (2001), 143–149.
126. Mikami, T., Yoshida, T., Akino, F., Motoori, T., Yajima, M., Okayasu, I., Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonic tumors. Association with survivin and bcl-2. Am J Clin Pathol 119 (2003), 723–730.
127. Svec, J., Musilkova, J., Bryndova, J., Jirasek, T., Mandys, V., Kment, M., et al. Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia. Inflamm Bowel Dis 16 (2010), 1127–1137.
128. Rapti, E., Gazouli, M., Legaki, E., Karamanolis, G., Thomas, D., Marinos, E., et al. Association of survivin promoter polymorphisms with inflammatory bowel disease and response to antitumor necrosis factor therapy. Genet Test Mol Biomarkers 19 (2015), 339–343.
129. Cohran, V., Managlia, E., Bradford, E.M., Goretsky, T., Li, T., Katzman, R.B., et al. Epithelial PIK3R1 (p85) and TP53 regulate survivin expression during adaptation to ileocecal resection. Am J Pathol 186 (2016), 1837–1846.
130. Hagemann, S., Wohlschlaeger, J., Bertram, S., Levkau, B., Musacchio, A., Conway, E.M., et al. Loss of survivin influences liver regeneration and is associated with impaired Aurora B function. Cell Death Differ 20 (2013), 834–844.
131. Bracht, T., Hagemann, S., Loscha, M., Megger, D.A., Padden, J., Eisenacher, M., et al. Proteome analysis of a hepatocyte-specific BIRC5 (survivin)-knockout mouse model during liver regeneration. J Proteome Res 13 (2014), 2771–2782.
132. Sanketh, D.S., Patil, S., Swetha, B., Oral lichen planus and epithelial dysplasia with lichenoid features: a review and discussion with special reference to diagnosis. J Investig Clin Dent, 2016.
133. Wei, J., Ma, D., Qiu, M., Dan, H., Zeng, X., Jiang, L., et al. Medical treatments for pregnant patients with oral lichen planus. Acta Odontol Scand 75 (2017), 67–72.
134. Oluwadara, O., Giacomelli, L., Christensen, R., Kossan, G., Avezova, R., Chiappelli, F., LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma. Bioinformation 4 (2009), 249–257.
135. Suganya, G., Bavle, R.M., Paremala, K., Makarla, S., Sudhakar, M., Reshma, V., Survivin expression in oral lichen planus: role in malignant transformation. J Oral Maxillofac Pathol 20 (2016), 234–238.
136. Santarelli, A., Mascitti, M., Rubini, C., Bambini, F., Zizzi, A., Offidani, A., et al. Active inflammatory biomarkers in oral lichen planus. Int J Immunopathol Pharmacol 28 (2015), 562–568.
137. Barrea, L., Savanelli, M.C., Di Somma, C., Napolitano, M., Megna, M., Colao, A., et al. Vitamin D and its role in psoriasis: an overview of the dermatologist and nutritionist. Rev Endocr Metab Disord, 2017.
138. Griffiths, C.E., van de Kerkhof, P., Czarnecka-Operacz, M., Psoriasis and atopic dermatitis. Dermatol Ther (Heidelb) 7 (2017), 31–41.
139. Bowen, A.R., Hanks, A.N., Murphy, K.J., Florell, S.R., Grossman, D., Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol 26 (2004), 177–181.
140. Gunduz, K., Temiz, P., Gencoglan, G., Inanir, I., Catalkaya, A., Expression of nuclear factor kappa B and survivin in psoriasis. ISRN Dermatol, 2012, 2012, 257059.
141. Wang, F., Zhang, X., Xia, P., Zhang, L., Zhang, Z., Enhancement of mRNA expression of survivin and human beta-defensin-3 in lesions of psoriasis vulgaris. Eur J Dermatol 26 (2016), 28–33.
142. Gudjonsson, J.E., Ding, J., Li, X., Nair, R.P., Tejasvi, T., Qin, Z.S., et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129 (2009), 2795–2804.
143. Dallaglio, K., Marconi, A., Truzzi, F., Lotti, R., Palazzo, E., Petrachi, T., et al. E-FABP induces differentiation in normal human keratinocytes and modulates the differentiation process in psoriatic keratinocytes in vitro. Exp Dermatol 22 (2013), 255–261.
144. Nagui, N.A., Abdel Hay, R.M., Rashed, L.A., Effect of narrow band ultraviolet B on survivin in psoriatic skin lesions. Eur J Dermatol 21 (2011), 866–869.
145. Gambichler, T., Terras, S., Skrygan, M., Cyclooxygenase 2 expression and apoptosis in normal and psoriatic epidermis models exposed to salt water soaks and narrowband ultraviolet B radiation. J Eur Acad Dermatol Venereol 29 (2015), 180–183.
146. Andersen, M.H., Pedersen, L.O., Capeller, B., Brocker, E.B., Becker, J.C., Thor Straten, P., Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61 (2001), 5964–5968.
147. Blanc-Brude, O.P., Mesri, M., Wall, N.R., Plescia, J., Dohi, T., Altieri, D.C., Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9 (2003), 2683–2692.
148. Reker, S., Becker, J.C., Svane, I.M., Ralfkiaer, E., Straten, P.T., Andersen, M.H., HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 108 (2004), 937–941.
149. Fenstermaker, R.A., Ciesielski, M.J., Qiu, J., Yang, N., Frank, C.L., Lee, K.P., et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother 65 (2016), 1339–1352.
150. Otto, K., Andersen, M.H., Eggert, A., Keikavoussi, P., Pedersen, L.O., Rath, J.C., et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23 (2005), 884–889.
151. Nitschke, N.J., Bjoern, J., Met, O., Svane, I.M., Andersen, M.H., Therapeutic vaccination against a modified minimal survivin epitope induces functional CD4 T cells that recognize survivin-expressing cells. Scand J Immunol 84 (2016), 191–193.
152. Ellebaek, E., Engell-Noerregaard, L., Iversen, T.Z., Froesig, T.M., Munir, S., Hadrup, S.R., et al. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 61 (2012), 1791–1804.
153. Schaft, N., Dorrie, J., Thumann, P., Beck, V.E., Muller, I., Schultz, E.S., et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 174 (2005), 3087–3097.
154. Berinstein, N.L., Karkada, M., Oza, A.M., Odunsi, K., Villella, J.A., Nemunaitis, J.J., et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology, 4, 2015, e1026529.
155. Firestein, G.S., McInnes, I.B., Immunopathogenesis of rheumatoid arthritis. Immunity 46 (2017), 183–196.
156. Kelly, R.J., Thomas, A., Rajan, A., Chun, G., Lopez-Chavez, A., Szabo, E., et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 24 (2013), 2601–2606.
157. Yamauchi, T., Nakamura, N., Hiramoto, M., Yuri, M., Yokota, H., Naitou, M., et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun 425 (2012), 711–716.
158. Tao, Y.F., Lu, J., Du, X.J., Sun, L.C., Zhao, X., Peng, L., et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer, 12, 2012, 619.
159. Glaros, T.G., Stockwin, L.H., Mullendore, M.E., Smith, B., Morrison, B.L., Newton, D.L., The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 70 (2012), 207–212.
160. Rauch, A., Hennig, D., Schafer, C., Wirth, M., Marx, C., Heinzel, T., et al. Survivin and YM155: how faithful is the liaison?. Biochim Biophys Acta 2014 (1845), 202–220.
161. Cheson, B.D., Bartlett, N.L., Vose, J.M., Lopez-Hernandez, A., Seiz, A.L., Keating, A.T., et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 118 (2012), 3128–3134.
162. Kaneko, N., Kita, A., Yamanaka, K., Mori, M., Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. Leuk Res 37 (2013), 1156–1161.
163. Tolcher, A.W., Quinn, D.I., Ferrari, A., Ahmann, F., Giaccone, G., Drake, T., et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 23 (2012), 968–973.
164. Raetz, E.A., Morrison, D., Romanos-Sirakis, E., Gaynon, P., Sposto, R., Bhojwani, D., et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol 36 (2014), 458–463.
165. Wiechno, P., Somer, B.G., Mellado, B., Chlosta, P.L., Cervera Grau, J.M., Castellano, D., et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol 65 (2014), 516–520.
166. Altieri, D.C., Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8 (2008), 61–70.
167. NCT01398462, Phase I clinical study of CWP232291 in acute myeloid leukemia patients. https://clinicaltrials.gov/ct2/show/NCT01398462 [accessed: 2017/04/26].
168. Tibes, R., McDonagh, K.T., Lekakis, L., Bogenberger, J.M., Kim, S., Frazer, N., et al. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Invest New Drugs 33 (2015), 389–396.
169. Shinohara, T., Sawada, H., Otsuki, S., Yodoya, N., Kato, T., Ohashi, H., et al. Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis. Am J Physiol Lung Cell Mol Physiol 308 (2015), L523–L538.
170. Kontny, E., Rudnicka, W., Chorazy-Massalska, M., Marcinkiewicz, J., Maslinski, W., Taurine chloramine inhibits proliferation of rheumatoid arthritis synoviocytes by triggering a p53-dependent pathway. Inflamm Res 55 (2006), 446–455.
171. Aggarwal, B.B., Kunnumakkara, A.B., Harikumar, K.B., Gupta, S.R., Tharakan, S.T., Koca, C., et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 1171 (2009), 59–76.
172. Guo, Y., Xu, F., Lu, T., Duan, Z., Zhang, Z., Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38 (2012), 904–910.
173. Fagard, R., Metelev, V., Souissi, I., Baran-Marszak, F., STAT3 inhibitors for cancer therapy: have all roads been explored?. JAKSTAT, 2, 2013, e22882.
174. Pratt, A.G., Swan, D.C., Richardson, S., Wilson, G., Hilkens, C.M., Young, D.A., et al. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis 71 (2012), 1374–1381.
175. Paulin, R., Meloche, J., Jacob, M.H., Bisserier, M., Courboulin, A., Bonnet, S., Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 301 (2011), H1798–H1809.
176. Schwartz, D.M., Bonelli, M., Gadina, M., O'Shea, J.J., Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12 (2016), 25–36.
177. Aoki, Y., Feldman, G.M., Tosato, G., Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003), 1535–1542.
178. Cohen, S.B., Tanaka, Y., Mariette, X., Curtis, J.R., Lee, E.B., Nash, P., et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis, 2017.
179. Shreberk-Hassidim, R., Ramot, Y., Zlotogorski, A., Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 76 (2017), 745–753, e19.
180. Banerjee, S., Biehl, A., Gadina, M., Hasni, S., Schwartz, D.M., JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77 (2017), 521–546.
181. Ortiz, M.A., Diaz-Torne, C., Hernandez, M.V., Reina, D., de la Fuente, D., Castellvi, I., et al. IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients. Clin Immunol 158 (2015), 174–182.